Welcome to our dedicated page for SeaStar Medical Holding news (Ticker: ICU), a resource for investors and traders seeking the latest updates and insights on SeaStar Medical Holding stock.
SeaStar Medical Holding Corp (ICU) is a pioneering medical technology company dedicated to mitigating the life-threatening consequences of hyperinflammation on vital organs. Operating within the healthcare and therapeutic technology industry, the company develops innovative extracorporeal therapies designed to address systemic inflammation by targeting effector cells, which are central to immune response dysregulation. These effector cells can cause direct tissue damage and release pro-inflammatory cytokines that exacerbate immune imbalances, leading to severe complications such as organ failure.
Core Business and Technology
At the heart of SeaStar Medical's operations is its proprietary technology aimed at reducing hyperinflammation. The company's extracorporeal therapies are engineered to selectively target and modulate effector cells, thereby interrupting the cycle of inflammation that can lead to organ damage. This approach represents a significant advancement in the treatment of conditions where systemic inflammation plays a critical role, such as acute kidney injury, sepsis, and other severe inflammatory disorders. By focusing on the root cause of immune dysregulation rather than merely addressing symptoms, SeaStar Medical offers a novel solution with the potential to improve patient outcomes and reduce healthcare costs.
Business Model and Revenue Generation
SeaStar Medical's business model centers on the development and commercialization of its proprietary therapies. Revenue streams likely include direct sales of its medical devices to healthcare providers, licensing agreements with pharmaceutical or biotechnology companies, and potential partnerships for co-development or distribution. The company’s focus on extracorporeal therapies positions it as a key player in a specialized market segment, where demand for innovative solutions to manage systemic inflammation is growing.
Market Context and Competitive Landscape
SeaStar Medical operates within the broader medical technology and therapeutic solutions industry, a sector characterized by rapid innovation and stringent regulatory requirements. The company’s focus on hyperinflammation addresses a critical unmet need in healthcare, particularly in the management of acute and chronic conditions that involve immune system dysregulation. Competitors in this space may include other firms specializing in extracorporeal therapies, immunomodulation technologies, or inflammation-targeting pharmaceuticals. However, SeaStar Medical differentiates itself through its proprietary focus on effector cells, offering a targeted approach that sets it apart from more generalized treatments.
Challenges and Opportunities
Like many companies in the medical technology sector, SeaStar Medical faces challenges such as navigating complex regulatory pathways, securing clinical validation for its therapies, and competing against well-established players. However, the company’s unique approach to targeting effector cells provides a competitive edge, particularly if clinical outcomes demonstrate significant efficacy and safety advantages. Additionally, the growing recognition of hyperinflammation as a critical factor in various medical conditions presents a substantial market opportunity for the company’s solutions.
Significance in the Healthcare Industry
SeaStar Medical’s innovative therapies have the potential to transform the management of systemic inflammation, offering new hope for patients suffering from conditions with limited treatment options. By addressing the underlying mechanisms of immune dysregulation, the company contributes to a paradigm shift in how inflammatory diseases are treated, emphasizing precision and targeted intervention. This positions SeaStar Medical as a significant player in the advancement of medical technology and therapeutic solutions.
SeaStar Medical Holding (Nasdaq: ICU), a commercial-stage medical device company, will present at NobleCon20, Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference.
The presentation is scheduled for Wednesday, December 4, 2024, at 12:00 p.m. Eastern time (9:00 a.m. Pacific time) in Boca Raton, Fla. The company will provide an overview of its proprietary solutions aimed at reducing the consequences of hyperinflammation on vital organs.
A webcast of the presentation will be available on the company's website starting December 5 and will be archived for 90 days.
SeaStar Medical has begun shipping QUELIMMUNE to its third hospital customer, marking the milestone of 100 therapeutic devices shipped since its commercial launch in July. QUELIMMUNE, the company's Selective Cytopheretic Device (SCD), treats critically ill children in ICU with acute kidney injury and sepsis. The company is on track to make QUELIMMUNE available in 4-5 leading pediatric hospitals by end of 2024. The device requires hospital-specific IRB approval and integration with existing hemodialysis equipment. Treatment typically requires 3-7 days, with daily cartridge replacement. Recent data presented at Kidney Week 2024 showed projected cost savings driven by lower expected death rates and shorter hospital stays versus standard care.
SeaStar Medical (ICU) reported Q3 2024 financial results, highlighting its first commercial sales of QUELIMMUNE™, generating revenue of $67,500. The company reported progress in its NEUTRALIZE-AKI pivotal trial with 59 subjects enrolled and expanded to 12 clinical sites. SeaStar eliminated over $9 million in long-term debt since early 2024. Q3 net loss was $4.5 million ($1.10 per share) compared to $7.2 million ($9.02 per share) in Q3 2023. Cash position as of September 30, 2024, was $2.1 million, bolstered by a $10 million registered direct offering in July 2024.
SeaStar Medical announces FDA Breakthrough Device Designation for its Selective Cytopheretic Device (SCD) to treat chronic systemic inflammation in end-stage renal disease patients requiring chronic hemodialysis. This marks the fourth Breakthrough designation for SCD, expanding the company's addressable U.S. patient population to 745,000 annually. The device targets over 480,000 U.S. individuals requiring in-center hemodialysis, with treatment costs around $100,000 per patient yearly. The SCD is designed to selectively target proinflammatory neutrophils and monocytes during continuous renal replacement therapy, potentially improving survival and quality of life for patients who currently face a 42% five-year survival rate.
SeaStar Medical (Nasdaq: ICU) reports record monthly enrollment of 10 patients in its NEUTRALIZE-AKI pivotal trial, bringing total enrollment to 56. The trial evaluates the company's Selective Cytopheretic Device (SCD) in adults with acute kidney injury receiving continuous renal replacement therapy. With 12 clinical sites now activated, including new teaching hospitals and military facilities, enrollment is expected to accelerate. The trial aims to enroll up to 200 adults, with an interim analysis planned at 100 subjects. The SCD has FDA Breakthrough Device Designation, and the trial received Category B coverage from Medicare & Medicaid for certain expenses.
SeaStar Medical (Nasdaq: ICU) has shipped QUELIMMUNE to its second hospital customer, marking its first sale since transitioning to a direct sales model. QUELIMMUNE, an FDA-approved Selective Cytopheretic Device (SCD) for treating critically ill children with acute kidney injury and sepsis, now generates 100% revenue recognition for the company. Recent data presented at ASN Kidney Week showed potential cost savings of approximately $30,000 per hospitalization using QUELIMMUNE, compared to standard care costs of $460,000. The company aims to make QUELIMMUNE available in 4-5 leading pediatric hospitals by end of 2024.
SeaStar Medical presented new economic data for its QUELIMMUNE device at ASN Kidney Week 2024, demonstrating significant cost-saving potential in treating pediatric acute kidney injury (AKI). Analysis shows hospitalization costs of $461,736 for pediatric AKI patients requiring CRRT, with QUELIMMUNE projected to save approximately $30,000 per hospitalization. The device achieves cost neutrality after 6 days of therapy and shows a 77% survival rate in children ≥10 kg and ≤22 years, compared to 50% standard care survival rate. The company presented four posters at the conference, including studies on the ongoing NEUTRALIZE-AKI pivotal trial and upcoming NEUTRALIZE-CRS trial.
SeaStar Medical presented economic analysis data for its QUELIMMUNE device at ASN Kidney Week 2024, demonstrating significant cost-saving potential in treating pediatric acute kidney injury (AKI). The analysis revealed that hospitalization costs for pediatric AKI patients requiring CRRT averaged $461,736, while treatment with QUELIMMUNE could save approximately $30,000 per hospitalization. The device achieves cost neutrality after 6 days of therapy and shows a 77% survival rate in children ≥10 kg, compared to 50% with standard care. The company also presented data on ongoing trials including NEUTRALIZE-AKI and NEUTRALIZE-CRS, highlighting their expanding therapeutic applications.
SeaStar Medical announces Stanford Medicine's clearance to enroll subjects in the NEUTRALIZE-AKI pivotal trial for their Selective Cytopheretic Device (SCD). The trial now has 12 active sites with 52 enrolled subjects, including two recently added Department of Defense medical centers. The study will evaluate SCD's safety and efficacy in adults with acute kidney injury (AKI) in ICU receiving continuous kidney replacement therapy (CKRT), aiming to enroll up to 200 adults. The primary endpoint focuses on 90-day mortality or dialysis dependency. The SCD previously received FDA Breakthrough Device Designation, and in July 2024, CMS granted Category B coverage for certain expenses in the trial.
SeaStar Medical Holding (Nasdaq: ICU) announces it has taken full responsibility for direct sales, marketing, and distribution of QUELIMMUNE™, its FDA-approved therapeutic device for treating pediatric acute kidney injury (AKI) due to sepsis. The company's CEO, Eric Schlorff, emphasizes their focus on a successful commercial rollout and their ability to fulfill customer demand. SeaStar Medical is streamlining relationships with Institutional Review Boards at pediatric hospitals and providing clinical training to integrate QUELIMMUNE into existing hemofiltration systems.
The company reports exceeding expectations with initial demand and multiple reorders from their first customer, Cincinnati Children's. By assuming direct distribution, SeaStar Medical will now recognize 100% of revenue generated from QUELIMMUNE sales in the U.S., corresponding to 3-4 times more revenue per unit. QUELIMMUNE, operating under the Humanitarian Device Exemption, has shown promising clinical results, including a 77% reduction in mortality rate and no dialysis dependency at Day 60 in pediatric AKI patients requiring continuous kidney replacement therapy.
FAQ
What is the current stock price of SeaStar Medical Holding (ICU)?
What is the market cap of SeaStar Medical Holding (ICU)?
What does SeaStar Medical Holding Corp specialize in?
How does SeaStar Medical's technology work?
What market does SeaStar Medical operate in?
What challenges does SeaStar Medical face?
What differentiates SeaStar Medical from competitors?
Who are the likely customers of SeaStar Medical?
What conditions can SeaStar Medical's therapies address?
How does SeaStar Medical generate revenue?
